Market News

Jet Capital Investors LP Has Decreased Coherus Biosciences (Call) (CHRS) Holding; Last Week Transcontinental Inc. (TSE:TCL.A) Coverage

Jet Capital Investors LP decreased Coherus Biosciences Inc (Call) (CHRS) stake by 17.84% reported in 2017Q2 SEC filing. Jet Capital Investors LP sold 44,600 shares as Coherus Biosciences Inc (Call) (CHRS)’s stock declined 0.89%. The Jet Capital Investors LP holds 205,400 shares with $2.95 million value, down from 250,000 last quarter. Coherus Biosciences Inc (Call) now has $527.30M valuation. The stock increased 3.41% or $0.3 during the last trading session, reaching $9.1. About 110,509 shares traded. Coherus Biosciences, Inc. (NASDAQ:CHRS) has risen 17.62% since December 4, 2016 and is uptrending. It has outperformed by 0.92% the S&P500.

Among 4 analysts covering Transcontinental Inc. (TSE:TCL.A), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Transcontinental Inc. had 26 analyst reports since August 27, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets on Tuesday, June 7 with “Sector Perform”. The firm earned “Sector Perform” rating on Friday, September 9 by RBC Capital Markets. Scotia Capital maintained Transcontinental Inc. (TSE:TCL.A) on Wednesday, April 19 with “Sector Perform” rating. National Bank Canada upgraded the stock to “Outperform” rating in Friday, October 27 report. The company was maintained on Wednesday, August 31 by RBC Capital Markets. The firm earned “Sector Perform” rating on Friday, June 17 by Scotia Capital. See Transcontinental Inc. (TSE:TCL.A) latest ratings:

27/10/2017 Broker: National Bank Canada Old Rating: Sector Perform New Rating: Outperform Old Target: $26.00 New Target: $32.00 Upgrade
08/09/2017 Broker: BMO Capital Markets Rating: Market Perform Old Target: $25.00 New Target: $26.00 Target Up
08/09/2017 Broker: Canaccord Genuity Rating: Old Target: $24.00 New Target: $25.00 Target Up
08/09/2017 Broker: IBC Rating: Old Target: $28.00 New Target: $29.00 Target Up
08/09/2017 Broker: National Bank Canada Rating: Sector Perform Old Target: $25.00 New Target: $26.00 Target Up
08/09/2017 Broker: RBC Capital Markets Rating: Sector Perform Old Target: $26.00 New Target: $27.00 Target Up
08/09/2017 Broker: Scotia Capital Rating: Sector Perform Old Target: $24.00 New Target: $26.50 Target Up
07/06/2017 Broker: RBC Capital Markets Rating: Sector Perform Old Target: $23.00 New Target: $24.00 Target Up

Among 10 analysts covering Coherus Biosciences (NASDAQ:CHRS), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Coherus Biosciences had 18 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was initiated by Barclays Capital with “Overweight” on Monday, November 23. The firm has “Buy” rating by Citigroup given on Wednesday, July 27. The firm earned “Hold” rating on Thursday, September 3 by Zacks. Maxim Group maintained it with “Buy” rating and $4000 target in Monday, June 12 report. The rating was initiated by Maxim Group with “Buy” on Wednesday, September 7. The rating was initiated by Credit Suisse on Wednesday, January 20 with “Outperform”. The firm earned “Buy” rating on Monday, June 12 by Cowen & Co. The stock has “Buy” rating by Robert W. Baird on Thursday, September 7. The stock has “Outperform” rating by Robert W. Baird on Wednesday, October 19. Credit Suisse maintained it with “Buy” rating and $17.0 target in Wednesday, September 27 report.

Investors sentiment increased to 2.09 in Q2 2017. Its up 0.41, from 1.68 in 2017Q1. It increased, as 15 investors sold CHRS shares while 18 reduced holdings. 20 funds opened positions while 49 raised stakes. 39.79 million shares or 8.50% more from 36.68 million shares in 2017Q1 were reported. D E Shaw & Co invested in 119,300 shares. Deutsche Comml Bank Ag reported 81,613 shares or 0% of all its holdings. Ubs Asset Mgmt Americas stated it has 0% of its portfolio in Coherus Biosciences, Inc. (NASDAQ:CHRS). Highbridge Mgmt Ltd Company owns 0.01% invested in Coherus Biosciences, Inc. (NASDAQ:CHRS) for 43,856 shares. Jennison Ltd Co, New York-based fund reported 18,200 shares. Moreover, Millennium Ltd Liability Corporation has 0% invested in Coherus Biosciences, Inc. (NASDAQ:CHRS) for 29,345 shares. Credit Suisse Ag has 0% invested in Coherus Biosciences, Inc. (NASDAQ:CHRS) for 149,752 shares. Knott David M reported 0.13% in Coherus Biosciences, Inc. (NASDAQ:CHRS). Aqr Ltd accumulated 13,900 shares or 0% of the stock. Orbimed Advsr Llc has 1.08M shares for 0.16% of their portfolio. Moreover, Rock Springs Capital Management LP has 0.5% invested in Coherus Biosciences, Inc. (NASDAQ:CHRS) for 693,900 shares. C World Group Holdings A S owns 241,505 shares for 0.05% of their portfolio. 21,900 were accumulated by Renaissance Technology Ltd Liability Corp. Moreover, Parallax Volatility Advisers Ltd Partnership has 0% invested in Coherus Biosciences, Inc. (NASDAQ:CHRS). Macquarie Gp Ltd has invested 0.01% of its portfolio in Coherus Biosciences, Inc. (NASDAQ:CHRS).

Analysts await Coherus Biosciences, Inc. (NASDAQ:CHRS) to report earnings on March, 12. They expect $-0.90 EPS, up 47.37% or $0.81 from last year’s $-1.71 per share. After $-1.09 actual EPS reported by Coherus Biosciences, Inc. for the previous quarter, Wall Street now forecasts -17.43% EPS growth.

Transcontinental Inc. engages in print, flexible packaging, publishing, and digital media activities in Canada and the United States. The company has market cap of $2.12 billion. The firm operates through Printing and Packaging Sector, and Media Sector divisions. It has a 10.8 P/E ratio. The Printing and Packaging Sector segment prints retail flyers, magazines, newspapers, color books, and personalized and mass marketing products; provides pre-media and geo-targeted door-to-door distribution services; and produces and sells flexible packaging solutions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *